A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small lung cancer (NSCLC)

被引：0
|
作者：
Camidge, D. R.
Ballas, M. S.
Dubey, S.
Haigentz, M.
Rosen, P. J.
Spicer, J. F.
West, H. J.
Shah, G. D.
Youssoufian, H.
Mita, A. C.
机构：
[1] Univ Colorado Denver, Aurora, CO USA
[2] NYU, Ctr Canc, New York, NY USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Montefiore Med Ctr, Bronx, NY 10467 USA
[5] Tower Canc Res Fdn, Beverly Hills, CA USA
[6] Guys Hosp, Div Canc Studies, Kings Coll London, London SE1 9RT, England
[7] Swedish Canc Inst, Seattle, WA USA
[8] ImClone Syst, New York, NY USA
[9] ImClone Syst, Branchburg, NJ USA
[10] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7588
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Hidehito Horinouchi
    Noboru Yamamoto
    Hiroshi Nokihara
    Takeshi Horai
    Makoto Nishio
    Fumiyoshi Ohyanagi
    Atsushi Horiike
    Kazuhiko Nakagawa
    Masaaki Terashima
    Takafumi Okabe
    Hiroyasu Kaneda
    Mark D. McKee
    Dawn M. Carlson
    Hao Xiong
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 37 - 43
  • [22] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Horai, Takeshi
    Nishio, Makoto
    Ohyanagi, Fumiyoshi
    Horiike, Atsushi
    Nakagawa, Kazuhiko
    Terashima, Masaaki
    Okabe, Takafumi
    Kaneda, Hiroyasu
    McKee, Mark D.
    Carlson, Dawn M.
    Xiong, Hao
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 37 - 43
  • [23] An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer
    Spigel, David R.
    Luft, Alexander
    Depenbrock, Henrik
    Ramlau, Rodryg
    Khalil, Mazen
    Kim, Joo-Hang
    Mayo, Carlos
    Chao, Grace Yi
    Obasaju, Coleman
    Natale, Ronald
    CLINICAL LUNG CANCER, 2017, 18 (05) : 480 - 488
  • [24] A PHASE 2 RANDOMIZED OPEN-LABEL STUDY OF RAMUCIRUMAB (IMC 1121B; RAM) IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS (PTS) WITH RECURRENT OR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM NON-SQUAMOUS (NSQ) PTS (NCT01160744)
    Doebele, R.
    Spigel, D.
    Tehfe, M.
    Thomas, S.
    Reck, M.
    Verma, S.
    Yurasov, S.
    Camidge, D. R.
    Bonomi, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 408 - 408
  • [25] A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC)
    Bommakanti, S.
    Larson, T.
    Dudek, A.
    Koopmeiners, J.
    Kumar, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
    Thomas, S.
    Doebele, R. C.
    Spigel, D.
    Tehfe, M.
    Reck, M.
    Verma, S.
    Zimmermann, A.
    Alexandris, E.
    Lee, P.
    Bonomi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS): Evaluation of recruits in Japan
    Ohe, Y.
    Ichinose, Y.
    Nishiwaki, Y.
    Yamamoto, N.
    Negoro, S.
    Duffield, E.
    Jiang, H.
    Saijo, N.
    Mok, T.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC)
    Faoro, L.
    Hainsworth, J. D.
    Karlin, D. A.
    Huang, J. E.
    Fang, L.
    Scappaticci, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Roger B. Cohen
    Corey J. Langer
    George Rajan Simon
    Peter David Eisenberg
    John Daniel Hainsworth
    Stefan Madajewicz
    Thomas Michael Cosgriff
    Kristen Pierce
    Huiping Xu
    Katherine Liau
    Diane Healey
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 81 - 89
  • [30] A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
    Villaruz, Liza C.
    Cobo, Manuel
    Syrigos, Konstantinos
    Mavroudis, Dimitrios
    Zhang, Wei
    Kim, Jong Seok
    Socinski, Mark A.
    LUNG CANCER, 2019, 136 : 52 - 56
12345